HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Like Consumer Health Ad Claims About COVID-19, Customer Testimonials Are False And Misleading

Executive Summary

Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading. 

You may also be interested in...



Elderberry Demand Loud But Matherson Organics Silent In NAD Review Of Immune Benefit Claim

The National Advertising Division says it will refer Matherson Organics to regulators for possible enforcement after it failed to provide a substantive response to an inquiry on an Instagram claim that suggested Vitamin Bounty Elderberry Immune Support could help prevent or treat COVID-19.

No Enforcement Immunity For Testimonials On Immunity Or Claims With 'Alert: No COVID-19 Cure'

Elderberry syrup marketer Provezza Health targeted review of claims consumers may link to COVID-19 prevention or treatment due to testimonials not dispelled by the firm. FDA and FTC warn CBD firm to discontinue claims noting immunity-boosting is the “best defense” against COVID-19.

Superfood Firm Calls Immunity Claim Ordinary, But Doesn’t Contest COVID-19 Inquiry

The firm immediately discontinued social media video conveying an implied message that using its Immunity Bundle protects against contracting COVID-19 after BBB National Programs requested evidence supporting the claim.

Related Content

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel